概括
输血处方的新计算机辅助验证过程提高了安全性. 这个系统提高了指导方针的遵守,减少了血液产品的暴露,并降低了整体医疗保健成本.
科学领域:
- 医疗信息学 医疗信息学
- 患者安全 患者安全
- 卫生系统管理管理卫生系统管理
背景情况:
- 输血处方需要严格验证,以确保患者安全并优化资源利用.
- 现有的手动验证流程可能耗时且容易出现错误,可能会影响患者的治疗结果和医疗保健成本.
研究的目的:
- 实施和评估对输血处方的系统计算机辅助验证过程.
- 评估这一过程对输血安全和资源利用的影响.
主要方法:
- 开发和实施计算机辅助系统,用于验证输血订单.
- 实施后系统监测指南的遵守和血液制品的使用情况.
- 分析与新验证过程相关的成本影响.
主要成果:
- 计算机辅助验证系统和验证的输血指南的高采用率.
- 显著减少患者接触血液制品的时间.
- 与输血相关的整体医疗保健成本的明显下降.
结论:
- 计算机辅助验证是提高输血安全的有效策略.
- 这种方法优化了资源分配,并降低了输血医学的成本.
- 系统的验证过程是改善患者结果和医疗保健效率的关键.
相关概念视频
Pre-Procedural Guidelines for Assessing Blood Pressure
Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the patient.
Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...


